Metraipolis › archive › dc_0af2001aa2f0

TACE combined with regorafenib with or without anti-PD-1 therapy for advanced HCC after targeted therapy failure: a multicenter real-world study — Europe PMC PMID:41179689

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41179689
DOI: 10.3389/fonc.2025.1652319
License (as archived): solo-consultazione
Archived: 2026-11-09T06:58:14.761Z
SHA-256 of the archived text: 8168a7e6405308fe6c5748f9ab0475779bbd8061e69a39b241e81070f3cdc328
Stable URL of this page: https://metraipolis.com/documento/dc_0af2001aa2f0

How to cite

TACE combined with regorafenib with or without anti-PD-1 therapy for advanced HCC after targeted therapy failure: a multicenter real-world study — Europe PMC PMID:41179689 — Europe PMC (en), https://europepmc.org/article/MED/41179689 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0af2001aa2f0 (Metraipolis archive dc_0af2001aa2f0, sha256 8168a7e6405308fe6c5748f9ab0475779bbd8061e69a39b241e81070f3cdc328)

BibTeX

@misc{dc0af2001aa2f0,
  title = {TACE combined with regorafenib with or without anti-PD-1 therapy for advanced HCC after targeted therapy failure: a multicenter real-world study — Europe PMC PMID:41179689},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41179689},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0af2001aa2f0; sha256 8168a7e6405308fe6c5748f9ab0475779bbd8061e69a39b241e81070f3cdc328},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41179689. Agents can read the archived copy with the MCP tool read_document.